Eisai Co. Ltd. said Thursday that it would pull its weight-loss drug Belviq off the market in the U.S. A long-term trial, which studied the drug's cardiovascular impact, was required as part of the Food and Drug Administration approval in 2012. This study found that people taking the drug reported higher rates of cancer than those taking the placebo. Eisai said it still believes Belviq has a positive benefit-risk profile for the patients for which it is indicated but would still pull the drug from the market. "Eisai's interpretation of the data from the Camellia-Timi 61 trial differs from that of the FDA," the company said in a news release. Eisai's stock is up 4% over the past year, compared to the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.58% , which has gained 22%.